88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

Global Ergothioneine Market Poised for Accelerated Growth as Scientific Validation and Synthetic Biology Reshape Industry Dynamics New Frost & Sullivan White Paper Highlights Emerging Opportunities Across Healthy Aging, Functional Nutrition, Personal Care, and Preventive Healthcare ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Stronger Together, Shaping the Future \| WuXi XDC and BioDlink Successfully Concluded 2026 Open Day WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration. The event brought together biotech customers, industry ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
PharmaBlock's First Peptide GMP Pilot-scale Plant at PharmaBlock Zhejiang Site Now Operational Next-Generation Peptide CRDMO Solutions Enabled by a Green and Intelligent Platform for Empowering Global Innovative Drug Development ... 2026-06-04T Chemical Health Care/Hospital Medical/Pharmaceuticals
Innovative Drug Update \| Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10 SHENZHEN, China , June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin ® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast ... 2026-06-04T Health Care/Hospital Medical/Pharmaceuticals
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA SAN FRANCISCO and SUZHOU, China , June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma GUANGZHOU, China , June 4, 2026 /PRNewswire/ -- Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
111, Inc. Announces First Quarter 2026 Unaudited Financial Results Continuing Transition toward a More Asset-Light and Operationally Efficient Business Model Net Revenue of Promotional Products (1) Increased by 70.2% and Gross Profit Rose by 75.0% Year-over-Year ... 2026-06-04T Health Care/Hospital Medical/Pharmaceuticals Retail
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S. SEOUL, South Korea , June 4, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows GLASGOW, Scotland , June 4, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63 rd ERA Congress, show that once-weekly semaglutide significantly improved health-related ... 2026-06-04T Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved